دورية أكاديمية
أعرض في EDS

Prevalence and associated factors for non-alcoholic fatty liver disease among adults in the South Asian Region: a meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Prevalence and associated factors for non-alcoholic fatty liver disease among adults in the South Asian Region: a meta-analysis.
المؤلفون: Niriella MA; Faculty of Medicine, Department of Medicine, University of Kelaniya, Ragama, Sri Lanka., Ediriweera DS; Health Data Science Unit, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka., Withanage MY; Faculty of Medicine, Department of Medicine, University of Kelaniya, Ragama, Sri Lanka., Darshika S; Faculty of Medicine, Department of Medicine, University of Kelaniya, Ragama, Sri Lanka., De Silva ST; Faculty of Medicine, Department of Medicine, University of Kelaniya, Ragama, Sri Lanka., Janaka de Silva H; Faculty of Medicine, Department of Medicine, University of Kelaniya, Ragama, Sri Lanka.
المصدر: The Lancet regional health. Southeast Asia [Lancet Reg Health Southeast Asia] 2023 May 24; Vol. 15, pp. 100220. Date of Electronic Publication: 2023 May 24 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 9918419282806676 Publication Model: eCollection Cited Medium: Internet ISSN: 2772-3682 (Electronic) Linking ISSN: 27723682 NLM ISO Abbreviation: Lancet Reg Health Southeast Asia Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Elsevier Ltd., [2022]-
مستخلص: Background: Non-alcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease worldwide. We estimated the prevalence and predefined associated factors for NAFLD among South-Asian adults.
Methods: We searched PubMed and included descriptive, epidemiological studies with satisfactory methodology, reporting the prevalence of NAFLD with ultrasound. Two authors screened and extracted data independently. Gender, urban/rural settings, general population and individuals with metabolic diseases (MetD) stratified the analysis. In addition, a random-effects meta-analysis of the prevalence and effect sizes of associations of NAFLD was performed.
Findings: Twenty-two publications were included after the quality assurance process. The difference in the NAFLD prevalence between the general population and people with MetD was found to be statistically significant (Q = 15.8, DF = 1, P < 0.001). The pooled overall prevalence of NAFLD in the general population was 26.9% (95% CI: 18.9-35.8%) with high heterogeneity. The prevalence was similar among men and women (Q = 0.06, DF = 1, P = 0.806). The NAFLD prevalence in the rural communities was 22.6% (95% CI: 13.6-33.1%), and the prevalence in urban communities was 32.9% (95% CI: 22.8-43.8%) and the difference was not statistically significant (Q = 1.92, DF = 1, P = 0.166). The pooled overall prevalence of NAFLD in patients with MetD was 54.1% (95% CI: 44.1-63.9%) with high heterogeneity. The pooled overall prevalence of NAFLD in the non-obese population was 11.7% (95% CI: 7.0-17.3%). The pooled prevalence of non-obese NAFLD in the NAFLD population was 43.4% (95% CI: 28.1-59.4%). Meta-analysis of binary variables showed that NAFLD in the South Asian population was associated with diabetes mellitus, hypertension, dyslipidaemia, general obesity, central obesity and metabolic syndrome. Gender was not associated with NAFLD.
Interpretation: The overall prevalence of NAFLD among adults in South Asia is high, especially in those with MetD, and a considerable proportion is non-obese. In the South Asian population, NAFLD was associated with diabetes mellitus, hypertension, dyslipidaemia, general obesity, central obesity, and metabolic syndrome.
Funding: None.
Competing Interests: None.
(© 2023 The Author(s).)
References: J Clin Exp Hepatol. 2022 May-Jun;12(3):818-829. (PMID: 35677499)
Diabetes Technol Ther. 2014 Jan;16(1):48-55. (PMID: 24028151)
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):246-250. (PMID: 30641706)
Indian J Public Health. 2016 Jan-Mar;60(1):26-33. (PMID: 26911214)
PLoS One. 2022 Feb 10;17(2):e0263768. (PMID: 35143562)
PLoS One. 2017 Oct 27;12(10):e0187066. (PMID: 29077769)
Clin Gastroenterol Hepatol. 2017 Apr;15(4):474-485. (PMID: 27581063)
Mymensingh Med J. 2013 Oct;22(4):649-54. (PMID: 24292291)
Obes Surg. 2015 Nov;25(11):2078-87. (PMID: 25835982)
PLoS One. 2015 Oct 29;10(10):e0140908. (PMID: 26512983)
Hepatology. 2016 Jul;64(1):19-22. (PMID: 26926530)
Pak J Pharm Sci. 2018 Jan;31(1):193-198. (PMID: 29348103)
Dig Dis Sci. 2008 Jul;53(7):1967-76. (PMID: 18030620)
Indian Heart J. 2014 Nov-Dec;66(6):574-9. (PMID: 25634387)
Dig Dis. 2022;40(6):734-744. (PMID: 34942625)
J Diabetes Investig. 2021 May;12(5):877-885. (PMID: 32961610)
Visc Med. 2020 Jun;36(3):198-205. (PMID: 32775350)
World J Gastroenterol. 2020 Nov 28;26(44):7046-7060. (PMID: 33311949)
Clin Nutr ESPEN. 2020 Aug;38:80-85. (PMID: 32690182)
Trop Gastroenterol. 2015 Jan-Mar;36(1):25-30. (PMID: 26591951)
Atherosclerosis. 2012 Aug;223(2):507-11. (PMID: 22748277)
Hepatology. 2016 Jul;64(1):73-84. (PMID: 26707365)
J Postgrad Med. 2011 Jul-Sep;57(3):257-8. (PMID: 21941075)
Diabetes Metab Syndr. 2019 Sep - Oct;13(5):2957-2960. (PMID: 31425963)
Clin Liver Dis. 2009 Nov;13(4):511-31. (PMID: 19818302)
World J Hepatol. 2013 May 27;5(5):281-7. (PMID: 23717739)
BMC Res Notes. 2011 Nov 24;4:513. (PMID: 22115060)
Hepatol Int. 2020 Dec;14(6):889-919. (PMID: 33006093)
Ann Hepatol. 2007 Jul-Sep;6(3):161-3. (PMID: 17786142)
J Assoc Physicians India. 2009 Mar;57:201-4. (PMID: 19588647)
Eur Endocrinol. 2020 Oct;16(2):152-155. (PMID: 33117448)
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18273-7. (PMID: 17114290)
Ann Gastroenterol. 2012;25(1):45-51. (PMID: 24713801)
Hepatology. 2018 Jan;67(1):328-357. (PMID: 28714183)
BMJ Open. 2020 Aug 3;10(8):e036663. (PMID: 32747349)
Pak J Med Sci. 2017 Jan-Feb;33(1):121-126. (PMID: 28367184)
BMJ Open Gastroenterol. 2020 Dec;7(1):. (PMID: 33376110)
Clin Res Hepatol Gastroenterol. 2019 Nov;43(6):638-645. (PMID: 31196707)
J Assoc Physicians India. 2013 Jul;61(7):448-53. (PMID: 24772746)
Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1065-1069. (PMID: 31336445)
J Gastroenterol Hepatol. 2009 Jul;24(7):1284-8. (PMID: 19476560)
J Gastroenterol Hepatol. 2012 Oct;27(10):1555-60. (PMID: 22741595)
BMC Cardiovasc Disord. 2016 Feb 12;16:37. (PMID: 26869052)
J Hepatol. 2019 Oct;71(4):793-801. (PMID: 31279902)
Kathmandu Univ Med J (KUMJ). 2019 Jul-Sept.;17(67):170-173. (PMID: 33305742)
Transl Gastroenterol Hepatol. 2020 Apr 05;5:16. (PMID: 32258520)
J Clin Transl Hepatol. 2017 Mar 28;5(1):76-81. (PMID: 28507930)
Hepatology. 2010 May;51(5):1593-602. (PMID: 20222092)
Hepatology. 2008 Aug;48(2):449-57. (PMID: 18627003)
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. (PMID: 28554682)
Trop Gastroenterol. 2013 Jul-Sep;34(3):153-8. (PMID: 24851524)
JGH Open. 2018 Mar 30;2(2):39-46. (PMID: 30483562)
Diabetes Res Clin Pract. 2009 Apr;84(1):84-91. (PMID: 19168251)
Endocr Pract. 2014 Dec;20(12):1249-57. (PMID: 25100370)
PLoS One. 2019 Apr 12;14(4):e0215326. (PMID: 30978266)
Euroasian J Hepatogastroenterol. 2019 Jan-Jun;9(1):9-13. (PMID: 31988860)
Cureus. 2019 Feb 19;11(2):e4099. (PMID: 31057993)
فهرسة مساهمة: Keywords: Associations; Meta-analysis; NAFLD; Non-alcoholic fatty liver disease; Pooled prevalence; Prevalence; South Asia
تواريخ الأحداث: Date Created: 20230824 Latest Revision: 20230829
رمز التحديث: 20230830
مُعرف محوري في PubMed: PMC10442973
DOI: 10.1016/j.lansea.2023.100220
PMID: 37614359
قاعدة البيانات: MEDLINE
الوصف
تدمد:2772-3682
DOI:10.1016/j.lansea.2023.100220